JP4166218B2 - アミノ−プロパノール誘導体 - Google Patents
アミノ−プロパノール誘導体 Download PDFInfo
- Publication number
- JP4166218B2 JP4166218B2 JP2004535500A JP2004535500A JP4166218B2 JP 4166218 B2 JP4166218 B2 JP 4166218B2 JP 2004535500 A JP2004535500 A JP 2004535500A JP 2004535500 A JP2004535500 A JP 2004535500A JP 4166218 B2 JP4166218 B2 JP 4166218B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- formula
- methyl
- mmol
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- MXZROAOUCUVNHX-UHFFFAOYSA-N 2-Aminopropanol Chemical class CCC(N)O MXZROAOUCUVNHX-UHFFFAOYSA-N 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 57
- 229910052799 carbon Inorganic materials 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 229910052760 oxygen Inorganic materials 0.000 claims description 23
- 150000003839 salts Chemical group 0.000 claims description 22
- -1 salt compound Chemical class 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 125000001153 fluoro group Chemical group F* 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 4
- 230000001684 chronic effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 2
- 238000000034 method Methods 0.000 description 42
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 29
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 27
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000007858 starting material Substances 0.000 description 13
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 10
- 239000012267 brine Substances 0.000 description 10
- 239000012044 organic layer Substances 0.000 description 10
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 8
- 238000007429 general method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 238000002425 crystallisation Methods 0.000 description 6
- 230000008025 crystallization Effects 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 230000001506 immunosuppresive effect Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- XKDANMLSJTYUPV-MRXNPFEDSA-N tert-butyl n-[(2r)-1-hydroxy-4-(4-hydroxyphenyl)-2-methylbutan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@](C)(CO)CCC1=CC=C(O)C=C1 XKDANMLSJTYUPV-MRXNPFEDSA-N 0.000 description 5
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 4
- JVIUOMCSCXPLGW-UHFFFAOYSA-N 4-[2-[4-(hydroxymethyl)-2-methyl-5h-1,3-oxazol-4-yl]ethyl]phenol Chemical compound C1OC(C)=NC1(CO)CCC1=CC=C(O)C=C1 JVIUOMCSCXPLGW-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003018 immunosuppressive agent Substances 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000012047 saturated solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical group C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- 101100236683 Homo sapiens MBTPS1 gene Proteins 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011260 co-administration Methods 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- UVPLIDRCNRJGFV-LJQANCHMSA-N tert-butyl n-[(2r)-1-hydroxy-2-methyl-4-[4-(4,4,5,5,5-pentafluoropentoxy)phenyl]butan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@](C)(CO)CCC1=CC=C(OCCCC(F)(F)C(F)(F)F)C=C1 UVPLIDRCNRJGFV-LJQANCHMSA-N 0.000 description 3
- 150000003536 tetrazoles Chemical class 0.000 description 3
- YEEFLZIZMHPFFY-UHFFFAOYSA-N 1-(2-iodoethyl)-4-phenylmethoxybenzene Chemical compound C1=CC(CCI)=CC=C1OCC1=CC=CC=C1 YEEFLZIZMHPFFY-UHFFFAOYSA-N 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
- YCCILVSKPBXVIP-UHFFFAOYSA-N 2-(4-hydroxyphenyl)ethanol Chemical compound OCCC1=CC=C(O)C=C1 YCCILVSKPBXVIP-UHFFFAOYSA-N 0.000 description 2
- JCUJAHLWCDISCC-UHFFFAOYSA-N 2-(4-phenylmethoxyphenyl)ethanol Chemical compound C1=CC(CCO)=CC=C1OCC1=CC=CC=C1 JCUJAHLWCDISCC-UHFFFAOYSA-N 0.000 description 2
- FBADWCHAKCHONV-UHFFFAOYSA-N 2-amino-2-[2-(4-phenylmethoxyphenyl)ethyl]propane-1,3-diol Chemical compound C1=CC(CCC(CO)(CO)N)=CC=C1OCC1=CC=CC=C1 FBADWCHAKCHONV-UHFFFAOYSA-N 0.000 description 2
- WDYVUKGVKRZQNM-UHFFFAOYSA-N 6-phosphonohexylphosphonic acid Chemical compound OP(O)(=O)CCCCCCP(O)(O)=O WDYVUKGVKRZQNM-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940122739 Calcineurin inhibitor Drugs 0.000 description 2
- 101710192106 Calcineurin-binding protein cabin-1 Proteins 0.000 description 2
- 102100024123 Calcineurin-binding protein cabin-1 Human genes 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- 206010012442 Dermatitis contact Diseases 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007818 Grignard reagent Substances 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- TYLYRNJXSTXEQB-MQNHUJCZSA-N N-[(3R)-4-tert-butylsilyloxy-3,4-dimethyl-1-[4-(6,6,6-trifluoro-1-hydroxyhexyl)phenyl]pentan-3-yl]acetamide Chemical compound C(C)(C)(C)[SiH2]OC([C@](CCC1=CC=C(C=C1)C(CCCCC(F)(F)F)O)(C)NC(C)=O)(C)C TYLYRNJXSTXEQB-MQNHUJCZSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ZAFLJLGNVIFOMX-UHFFFAOYSA-N [2-methyl-4-[2-(4-phenylmethoxyphenyl)ethyl]-5h-1,3-oxazol-4-yl]methanol Chemical compound C1OC(C)=NC1(CO)CCC(C=C1)=CC=C1OCC1=CC=CC=C1 ZAFLJLGNVIFOMX-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- CMBKNTZEFNLDIN-UHFFFAOYSA-N diethyl 2-acetamido-2-[2-(4-phenylmethoxyphenyl)ethyl]propanedioate Chemical compound C1=CC(CCC(C(=O)OCC)(NC(C)=O)C(=O)OCC)=CC=C1OCC1=CC=CC=C1 CMBKNTZEFNLDIN-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000004795 grignard reagents Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- JDAKPBBWYIWXJF-UHFFFAOYSA-N n,n-diethyl-1,5-dihydro-2,4,3-benzodioxaphosphepin-3-amine Chemical compound C1OP(N(CC)CC)OCC2=CC=CC=C21 JDAKPBBWYIWXJF-UHFFFAOYSA-N 0.000 description 2
- FTDWNMSHJXLOKK-UHFFFAOYSA-N n-[1-hydroxy-2-(hydroxymethyl)-4-(4-phenylmethoxyphenyl)butan-2-yl]acetamide Chemical compound C1=CC(CCC(CO)(CO)NC(=O)C)=CC=C1OCC1=CC=CC=C1 FTDWNMSHJXLOKK-UHFFFAOYSA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- BZHUDNXPTGEPLF-PFEQFJNWSA-N (2r)-2-amino-2-methyl-4-[4-(4,4,5,5,5-pentafluoropentoxy)phenyl]butan-1-ol;hydrochloride Chemical compound Cl.OC[C@@](N)(C)CCC1=CC=C(OCCCC(F)(F)C(F)(F)F)C=C1 BZHUDNXPTGEPLF-PFEQFJNWSA-N 0.000 description 1
- KCNUIZYLKSXAIV-QGZVFWFLSA-N (2r)-2-amino-2-methyl-4-[4-(7,7,7-trifluoroheptyl)phenyl]butan-1-ol Chemical compound OC[C@@](N)(C)CCC1=CC=C(CCCCCCC(F)(F)F)C=C1 KCNUIZYLKSXAIV-QGZVFWFLSA-N 0.000 description 1
- OBXCGJYKRRGWEQ-PKLMIRHRSA-N (2r)-2-amino-4-[4-(5-fluoropentoxy)phenyl]-2-methylbutan-1-ol;hydrochloride Chemical compound Cl.OC[C@@](N)(C)CCC1=CC=C(OCCCCCF)C=C1 OBXCGJYKRRGWEQ-PKLMIRHRSA-N 0.000 description 1
- OFJKRYUZRSAUMU-HXUWFJFHSA-N (2r)-2-amino-4-[4-[2-(4-methoxyphenyl)ethoxy]phenyl]-2-methylbutan-1-ol Chemical compound C1=CC(OC)=CC=C1CCOC1=CC=C(CC[C@@](C)(N)CO)C=C1 OFJKRYUZRSAUMU-HXUWFJFHSA-N 0.000 description 1
- 150000000185 1,3-diols Chemical class 0.000 description 1
- ORLCKNCXHWNOCD-MRXNPFEDSA-N 1-[4-[(3r)-3-amino-4-hydroxy-3-methylbutyl]phenyl]-6,6,6-trifluorohexan-1-one Chemical compound OC[C@@](N)(C)CCC1=CC=C(C(=O)CCCCC(F)(F)F)C=C1 ORLCKNCXHWNOCD-MRXNPFEDSA-N 0.000 description 1
- DOGCTUGYGZGSFX-UHFFFAOYSA-N 1-aminopropane-1,3-diol Chemical compound NC(O)CCO DOGCTUGYGZGSFX-UHFFFAOYSA-N 0.000 description 1
- OEPRBXUJOQLYID-UHFFFAOYSA-N 1-fluoropentane Chemical compound CCCCCF OEPRBXUJOQLYID-UHFFFAOYSA-N 0.000 description 1
- ABUFEAKDTQPJQZ-UHFFFAOYSA-N 2,2-diethylbutane-1,1,1-triol Chemical compound CCC(CC)(CC)C(O)(O)O ABUFEAKDTQPJQZ-UHFFFAOYSA-N 0.000 description 1
- CTZFMMKZSPJHOS-UHFFFAOYSA-N 2-(3-fluoro-4-methoxyphenyl)ethanol Chemical compound COC1=CC=C(CCO)C=C1F CTZFMMKZSPJHOS-UHFFFAOYSA-N 0.000 description 1
- ORTPEEDBOZIXNC-UHFFFAOYSA-N 2-(4-methoxyphenyl)ethyl methanesulfonate Chemical compound COC1=CC=C(CCOS(C)(=O)=O)C=C1 ORTPEEDBOZIXNC-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- HFODWBXOYJGERK-UHFFFAOYSA-N 2-amino-2-[2-[4-(4,4,4-trifluorobutoxy)phenyl]ethyl]propane-1,3-diol Chemical compound OCC(N)(CO)CCC1=CC=C(OCCCC(F)(F)F)C=C1 HFODWBXOYJGERK-UHFFFAOYSA-N 0.000 description 1
- GDQASKHJRMADCW-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-(3-fluoro-4-methoxyphenyl)ethoxy]phenyl]ethyl]propane-1,3-diol Chemical compound C1=C(F)C(OC)=CC=C1CCOC1=CC=C(CCC(N)(CO)CO)C=C1 GDQASKHJRMADCW-UHFFFAOYSA-N 0.000 description 1
- QNEAWUFJGBLBJD-UHFFFAOYSA-N 2-methyl-4-[4-(4,4,4-trifluorobutoxy)phenyl]butan-2-amine Chemical compound NC(C)(C)CCC1=CC=C(C=C1)OCCCC(F)(F)F QNEAWUFJGBLBJD-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- DBCAQXHNJOFNGC-UHFFFAOYSA-N 4-bromo-1,1,1-trifluorobutane Chemical compound FC(F)(F)CCCBr DBCAQXHNJOFNGC-UHFFFAOYSA-N 0.000 description 1
- SPXOTSHWBDUUMT-UHFFFAOYSA-M 4-nitrobenzenesulfonate Chemical compound [O-][N+](=O)C1=CC=C(S([O-])(=O)=O)C=C1 SPXOTSHWBDUUMT-UHFFFAOYSA-M 0.000 description 1
- TVEXGJYMHHTVKP-UHFFFAOYSA-N 6-oxabicyclo[3.2.1]oct-3-en-7-one Chemical compound C1C2C(=O)OC1C=CC2 TVEXGJYMHHTVKP-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- VCURSOJNXCWUHJ-MRXNPFEDSA-N C[C@@](CCc(cc1)ccc1OCCCCCF)(CO)N Chemical compound C[C@@](CCc(cc1)ccc1OCCCCCF)(CO)N VCURSOJNXCWUHJ-MRXNPFEDSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- KZSNJWFQEVHDMF-SCSAIBSYSA-N D-valine Chemical compound CC(C)[C@@H](N)C(O)=O KZSNJWFQEVHDMF-SCSAIBSYSA-N 0.000 description 1
- 229930182831 D-valine Natural products 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102100025390 Integrin beta-2 Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 108010064600 Intercellular Adhesion Molecule-3 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
- 206010022680 Intestinal ischaemia Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
- 102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
- 101000686985 Mouse mammary tumor virus (strain C3H) Protein PR73 Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- AQJHALCQLMJDJL-HXUWFJFHSA-N N-[(3R)-4-tert-butylsilyloxy-1-(4-formylphenyl)-3,4-dimethylpentan-3-yl]acetamide Chemical compound C(C)(C)(C)[SiH2]OC([C@](CCC1=CC=C(C=C1)C=O)(C)NC(C)=O)(C)C AQJHALCQLMJDJL-HXUWFJFHSA-N 0.000 description 1
- LIZAYXCPDPVCNK-XMMPIXPASA-N N-[(3R)-4-tert-butylsilyloxy-3,4-dimethyl-1-[4-(6,6,6-trifluorohexanoyl)phenyl]pentan-3-yl]acetamide Chemical compound C(C)(C)(C)[SiH2]OC([C@](CCC1=CC=C(C=C1)C(CCCCC(F)(F)F)=O)(C)NC(C)=O)(C)C LIZAYXCPDPVCNK-XMMPIXPASA-N 0.000 description 1
- KCGIBCGHTYJHGP-RUZDIDTESA-N N-[(3R)-4-tert-butylsilyloxy-3,4-dimethyl-1-[4-(7,7,7-trifluoroheptyl)phenyl]pentan-3-yl]acetamide Chemical compound C(C)(C)(C)[SiH2]OC([C@](CCC1=CC=C(C=C1)CCCCCCC(F)(F)F)(C)NC(C)=O)(C)C KCGIBCGHTYJHGP-RUZDIDTESA-N 0.000 description 1
- HIEKJRVYXXINKH-ADVKXBNGSA-N N1([C@H]2CC[C@H](C[C@H]2OC)/C=C(\C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]3(O)O[C@@H]([C@H](C[C@H]3C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]2C)=O)CC)C=NN=N1 Chemical compound N1([C@H]2CC[C@H](C[C@H]2OC)/C=C(\C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]3(O)O[C@@H]([C@H](C[C@H]3C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]2C)=O)CC)C=NN=N1 HIEKJRVYXXINKH-ADVKXBNGSA-N 0.000 description 1
- ZIPYYPACLYBAPY-UHFFFAOYSA-N NC(CCc(cc1)ccc1OCCCCCC(F)(F)F)(CO)COP(O)(O)=O Chemical compound NC(CCc(cc1)ccc1OCCCCCC(F)(F)F)(CO)COP(O)(O)=O ZIPYYPACLYBAPY-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000013901 Nephropathies and tubular disease Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 206010044541 Traumatic shock Diseases 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- DUBUYWWNIFTYNG-UHFFFAOYSA-N [2-methyl-4-[2-[4-(6,6,6-trifluorohexoxy)phenyl]ethyl]-5h-1,3-oxazol-4-yl]methanol Chemical compound C1OC(C)=NC1(CO)CCC1=CC=C(OCCCCCC(F)(F)F)C=C1 DUBUYWWNIFTYNG-UHFFFAOYSA-N 0.000 description 1
- ZQRMABOIGAHMIA-UHFFFAOYSA-N [4-[2-[4-[2-(3-fluoro-4-methoxyphenyl)ethoxy]phenyl]ethyl]-2-methyl-5h-1,3-oxazol-4-yl]methanol Chemical compound C1=C(F)C(OC)=CC=C1CCOC(C=C1)=CC=C1CCC1(CO)N=C(C)OC1 ZQRMABOIGAHMIA-UHFFFAOYSA-N 0.000 description 1
- PRPAGESBURMWTI-UHFFFAOYSA-N [C].[F] Chemical group [C].[F] PRPAGESBURMWTI-UHFFFAOYSA-N 0.000 description 1
- YPNPLCUQNNKQBJ-UHFFFAOYSA-N acetamide;propanedioic acid Chemical compound CC(N)=O.OC(=O)CC(O)=O YPNPLCUQNNKQBJ-UHFFFAOYSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- NBLAIKHFQBOVPV-UHFFFAOYSA-N bis(ethoxycarbonyl)azaniumylideneazanide Chemical compound CCOC(=O)[N+](=[N-])C(=O)OCC NBLAIKHFQBOVPV-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 238000004517 catalytic hydrocracking Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000000 cycloalkoxy group Chemical group 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- YEWZQCDRZRYAEB-UHFFFAOYSA-N ditert-butyl hydrogen phosphate Chemical compound CC(C)(C)OP(O)(=O)OC(C)(C)C YEWZQCDRZRYAEB-UHFFFAOYSA-N 0.000 description 1
- YEWZQCDRZRYAEB-UHFFFAOYSA-M ditert-butyl phosphate Chemical compound CC(C)(C)OP([O-])(=O)OC(C)(C)C YEWZQCDRZRYAEB-UHFFFAOYSA-M 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- RZTAMFZIAATZDJ-UHFFFAOYSA-N felodipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-UHFFFAOYSA-N 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 208000001875 irritant dermatitis Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229940124302 mTOR inhibitor Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229950000844 mizoribine Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960001302 ridaforolimus Drugs 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 125000002345 steroid group Chemical group 0.000 description 1
- 231100000617 superantigen Toxicity 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- FIQMHBFVRAXMOP-UHFFFAOYSA-N triphenylphosphane oxide Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)C1=CC=CC=C1 FIQMHBFVRAXMOP-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229960004295 valine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 1
- 229950009819 zotarolimus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/094—Esters of phosphoric acids with arylalkanols
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
Description
R1は、所望によりOH、C1−2アルコキシまたは1個から6個のフッ素原子で置換されているC1−6アルキル;C2−6アルケニル;またはC2−6アルキニルであり;
R2はR2'またはR2”であり、
ここで、R2'はX1、−O−X1、−CO−X1、−CH(OH)−X1、−C(NOR6)−X1、−S−X1、−SO−X1、−SO2−X1または−N(C1−6アルキル)−X1(ここで、X1は、1個から17個のフッ素原子で置換されており、所望により炭素鎖を1個またはそれ以上のO、C=O、CH−OHまたはC=NOR6でおよび/または1個の炭素−炭素二重結合または三重結合で中断されているC3−8アルキル;C1−3アルキルで置換されており、所望により炭素鎖を1個またはそれ以上のO、C=O、CH−OHまたはC=NOR6でおよび/または1個の炭素−炭素二重結合または三重結合で中断されているペンチル;C2−8アルキル部分が、所望により炭素鎖を1個またはそれ以上のO、C=O、CH−OHまたはC=NOR6でおよび/または1個の炭素−炭素二重結合または三重結合で中断されており、C3−6シクロアルキルおよび/またはC2−8アルキルが1個から17個のフッ素原子で置換されているC2−8アルキル−C3−6シクロアルキルであり;各R6は、独立してH、C1−4アルキル、C2−4アルケニル、C2−4アルキニルまたはベンジルである)であり;そして
R2”は、パラ位に結合しているX−CH2−CH2−Rであり、ここで、XはO;CH2;またはC=Oであり;そしてRは式(b)
の残基であるか;またはRは、上記R7からR11に関して定義の1個から5個の置換基で所望により置換されているα−またはβ−ナフチルであり;
R3はZ−X2であり、ここで、ZはCH2、CHF、CF2またはCHMeであり、X2はOHまたは式(a)
の残基であり;そして
R4およびR5の各々はH、所望により1個、2個または3個のハロゲン原子で置換されているC1−4アルキル、またはアシルである。〕
の化合物を提供する。
好ましくは、R2'のアルキル基または部分は、少なくとも2個のフッ素原子、より好ましくは少なくとも3個の、特に3個から8個のフッ素炭素原子を含む。フッ素原子は、好ましくはR2中のアルキル基またはアルキル部分の末端炭素原子、すなわちフェニル基から離れた末端に存在する1個、2個または3個の水素原子を置き換える。末端炭素原子は、最後のおよび/または最後から2番目の、および/または最後から3番目のなど、最後の8個の炭素原子までを意味する。
R2'は好ましくはパラ位に存在する。
Yは直接結合、O、CO、CHOHまたはC=NOR6であり、ここで、R6は上記で定義の通りであり;
nは0、1,2、3、4または5であり;
mは0、1、2、3、4、5または6であるが、但し、n+mの合計が3−8であり、
pおよびqの各々は独立して0、1、2または3であり、
鎖(CH2)n−(CF2)m−CHpFqは、所望により1個の炭素−炭素二重結合または三重結合、1個のCOまたは1個または2個の酸素原子で中断されている。〕
の残基である。
−Y−CnF2n+1(ここで、n=3−8であり、そしてYはCH2、OまたはC=Oである);
−Y−CH2CnF2n+1(ここで、n=1−7であり、そしてYはCH2、OまたはC=Oである);
−Y−CH2CH2CnF2n+1(ここで、n=1−6であり、そしてYはCH2、OまたはC=Oである);
−Y−CH2CH2CH2CnF2n+1(ここで、n=1−5であり、そしてYはCH2、OまたはC=Oである);
−Y−(CH2)nF(ここで、n=1−7であり、そしてYはCH2、OまたはC=Oである);
−Y−(CH2)nCF3(ここで、n=1−6であり、そしてYはCH2、OまたはC=Oである);
−Y−(CH2)nCF2CH3(ここで、n=1−4であり、そしてYはCH2、OまたはC=Oである);
−Y−(CH2)n(CF2)mCHF2(ここで、n=0−3、m=1−6、n+m=3−7であり、そしてYはCH2、OまたはC=Oである);または
−Y−(CH2)nC(O)CF3(ここで、n=1−5であり、そしてYはCH2、OまたはC=Oである)。
である。好ましくは、R2'のフェニル環への結合は、Oを介する。
−R7からR11の各々は独立してCl、Br、F、CF3、OCF3、C1−6アルキル、C1−6アルコキシまたは所望により置換されているフェニル、および/または
−R7からR11の1個または2個の残基はHではなく、R7からR11の残りの残基がHである。
好ましくは、ZはCH2である。
好ましくは、X2はOHまたはOPO3H2である。
好ましくは、R1はメチル;エチルまたはOHで置換されているC1−5アルキルである。
a)R3がZ−X2であり、X2がOHである式Iの化合物に関して、式II
の化合物に存在する保護基を除去するか、または
b)R3がZ−X2であり、X2が式(a)の残基である式Iの化合物に関して、式III
の残基である}
である。〕
の化合物に存在する保護基を除去し、
必要な場合、遊離形で得た式Iの化合物を塩に変換するか、またはその逆を行うことを含む。
の化合物をアルキル化し、所望の残基X1または−CH2−CH2−Rを挿入することを含む。
以下の実施例は、本発明を説明する。融点は未補正である。
a)tert−ブチル{(R)−1−ヒドロキシ−2−メチル−4−[4−(4,4,5,5,5−ペンタフルオロ−ペンチルオキシ)−フェニル]−ブチ−2−イル}−カルバメート
一般法・方法A1(ポリスチレン−トリフェニルホスフィンを使用した光延反応;スキーム1)
tert−ブチル[(R)−1−ヒドロキシ−4−(4−ヒドロキシ−フェニル)−2−メチル−ブチ−2−イル]−カルバメート(100mg、0.34mmol)および4,4,5,5,5−ペンタフルオロペンタン−1−オール(50μl、0.37mmol、1.1当量)の乾燥THF(5ml)溶液に、トリフェニルホスフィン−ポリスチレン1.10mmol.g−1(370mg、0.41mmol、1.2当量)を添加する。懸濁液を15分震盪し、樹脂を膨張させる。次いで、ジエチルアゾジカルボキシレート(67μl、0.41mmol、1.2当量)を一度に注入する。得られた懸濁液を、アルゴン下、RTで一晩浸透する。次いで、ポリマーを濾取し、THF(3×2ml)で洗浄する。合わせた濾液の蒸発により、黄色半結晶残渣を得る。フラッシュクロマトグラフィー(FlashMaster II、MTBE/ヘキサン勾配:0%MTBE→30%MTBE、30分以内;30%MTBE→60%MTBE、10分以内)での精製により、無色結晶を得る:融点90−92℃、MS(ESI+): 456(MH+), 400(MH+ - tBu), 356(MH+ - Boc), 1H-NMR(400 MHz, CDCl3): δ 1.16(s, 3H, 2-Me), 1.37(s, 9H, tBu), 1.79(cm, 1H, 3-CHα), 1.91-2.04(m, 3H, 3-CHα + 2'-CH2), 2.12-2.28(m, 2H, 3'-CH2), 2.51(cm, 2H, 4-CH2Ar), 3.58(d, 1H, 2J=10.9, 1-CHα), 3.63(d, 1H,, 2J=11.2, 1-CHβ), 3.94(t, 3H, 3J=7.3, 1'-ArOCH2), 6.75(d', 2H, J=10.2, ArH), 7.05(d', J=10.5, ArH)。
tert−ブチル[(R)−1−ヒドロキシ−4−(4−ヒドロキシ−フェニル)−2−メチル−ブチ−2−イル]−カルバメート(1.48g、5mmol)、4,4,5,5,5−ペンタフルオロペンタン−1−オール(0.74ml、5.5mmol)およびトリフェニルホスフィン(1.39g、5.25mmol)の無水THF(50ml)溶液を氷浴に入れる。10分撹拌後、ジエチルジアゾジカルボキシレート(0.87ml、5.25mmol)を、ゆっくり15分にわたり注入する。添加の終了後、氷浴を除去し、ここで薄黄色反応混合物をRTでアルゴン下一晩撹拌する。次いで、溶媒を蒸発させ、残渣をMTBE/ヘキサンから再結晶して、反応で形成したほとんどのジエチルヒドラジノジカルボキシレートおよびトリフェニルホスフィンオキシドを除去する。母液を蒸発乾固する。フラッシュクロマトグラフィー(溶離剤:MTBE/ヘキサン 1:2)による精製により、表題化合物を無色結晶として得る。
表題化合物を、下記のスキームにしたがい製造できる。出発物質として、L−バリンとアラニンAまたはD−バリンとグリシンBのいずれかから得たSchoellkopf試薬を使用できる。
a)tert−ブチル{(R)−1−ヒドロキシ−2−メチル−4−[5−フルオロ−ペンチルオキシ)−フェニル]−ブチ−2−イル}−カルバメート
一般法・方法B1(アルキル化反応;スキーム1)
tert−ブチル[(R)−1−ヒドロキシ−4−(4−ヒドロキシ−フェニル)−2−メチル−ブチ−2−イル]−カルバメート(200mg、0.68mmol、実施例1b)および1−ブロモ−5−フルオロペンタン(172mg、1.02mmol、1.5当量)の無水DMF(2.5ml)溶液に、無水炭酸セシウム(331mg、1.02mmol、1.5当量)を添加する。得られた懸濁液を一晩、60℃で防湿しながら撹拌する。RTに冷却した後、固体を濾取し、DMF(2×1ml)で濯ぐ。合わせた濾液を高真空で蒸発させ、濃オレンジ色シロップを得る。フラッシュクロマトグラフィー(FlashMaster II、実施例1aに記載のようなMTBE/ヘキサン勾配)での精製により、無色結晶として得る:融点91−93℃、ESI+ MS: m/z=406(MNa+), 384(MH+), 328(MH+ - tBu), 1H-NMR(400 MHz, CDCl3): δ 1.23(s, 3H, 2-Me), 1.46(s, 9H, tBu), 1.60(cm, 2H, 3'-CH2), 1.74(cm, 1H, 3-CHα), 1.77-1.90(m, 4H, 2'- & 4'-CH2), 2.03(cm, 1H, 3-CHβ), 2.48-2.69(m, 2H, 4-CH2), 3.64(br d, 1H, 2J=11.3, 1-CHα), 3.72(br d, 1H, 2J=11.9, 1-CHβ), 3.96(t, 2H, J=7.1, 1'-OCH2), 4.03(br, 1H, OH), 4.48(dt, 2H, 2JH,F=47.8, 3JH,H=7.2, 5'-CH2F), 4.62(br s, 1H, NH), 6.80(d', 2H, J=10.1, ArH), 7.08(d', J=10.3, ArH)。
(R)−3−{4−[2−(4−メトキシ−フェニル)−エトキシ]−フェニル}−1−ヒドロキシメチル−1−メチル−プロピル)−カルバミン酸tert−ブチルエステル、一般法・方法B2(アルキル化反応;スキーム1)
tert−ブチル[(R)−1−ヒドロキシ−4−(4−ヒドロキシ−フェニル)−2−メチル−ブチ−2−イル]−カルバメート(0.1mol)およびメタンスルホン酸4−メトキシ−フェネチルエステル(0.1mol)のエタノール(500ml)溶液に、炭酸カリウム(0.3mol)を添加する。懸濁液を70℃で16時間撹拌し、RTに冷却する。濾過後、溶媒を蒸発し、粗残渣をシリカゲルおよびCH2Cl2/MeOH=20/1を使用したクロマトグラフィーで精製し、白色結晶性固体を得る。
a)N−{(R)−1−(tert−ブチル−ジメチル−シラニルオキシメチル)−1−メチル−3−[4−(6,6,6−トリフルオロ−1−ヒドロキシ−ヘキシル)−フェニル]−プロピル}−アセトアミド
N−[(R)−1−(tert−ブチル−ジメチル−シラニルオキシメチル)−3−(4−ホルミル−フェニル)−1−メチル−プロピル]−アセトアミド(0.1mol)の乾燥THF溶液に、5−トリフルオロペンチルマグネシウムブロミド(対応するブロミド(0.45mol)とマグネシウム削りくずから得る)のTHF溶液を添加する。RTで2時間撹拌後、反応混合物を水でクエンチし、AcOEt(3×)で抽出する。有機相を1N HCl、飽和水性NaHCO3および水で洗浄する。乾燥(MgSO4)および溶媒の蒸発後、表題化合物を、シリカゲルおよびAcOEt/ヘキサン=3/7を使用したクロマトグラフィーにより精製する。
塩化オキザリル(0.15mmol)のCH2Cl2溶液に、−78℃で最初にDMSO(0.2mmol)、次いでN−{(R)−1−(tert−ブチル−ジメチル−シラニルオキシメチル)−1−メチル−3−[4−(6,6,6−トリフルオロ−1−ヒドロキシ−ヘキシル)−フェニル]−プロピル}−アセトアミド(0.1mmol)のCH2Cl2溶液を添加する。1時間、−78℃で撹拌後、トリエチルアミン(0.7mmol)を添加し、混合物をRTに暖める。水でクエンチし、続いてAcOEtで抽出する。乾燥(MgSO4)後、溶媒を蒸発する。
tert−ブチル{(R)−2−メチル−2−(3−オキソ−1,5−ジヒドロ−3λ5−ベンゾ[e][1,3,2]ジオキサホスフェピン−3−イルオキシ)−4−[4−(4,4,5,5,5−ペンタフルオロ−ペンチルオキシ)−フェニル]−ブチ−2−イル}−カルバメート(32mg、0.05mmol)のメタノール溶液に、Pd/C 10%(50mg)を添加する。懸濁液を窒素でパージし、次いで大気圧中で、穏やかに撹拌しながら2時間水素化する。その後、触媒を濾取し、濾液を蒸発乾固し、無色樹脂を得る。残渣をジオキサン(0.75ml)に再溶解し、4M HClのジオキサン(0.25ml)溶液を添加する。2時間撹拌後、わずかに濁った溶液を蒸発させる。無色半固体残渣を乾燥エーテル(5ml)と共に超音波処理し、無色沈殿を得る。固体を濾取し、乾燥エーテルで洗浄し、無色粉末を得る:融点229−231℃、MS(ESI+): 434(M-H-), 1H-NMR(400 MHz, CD3OD): δ 1.37(s, 3H, 2-Me), 1.88(cm, 1H, 3-CHα), 1.94-2.09(m, 3H, 3-CHα + 2'-CH2), 2.32(cm, 2H, 3'-CH2), 2.64(cm, 2H, 4-CH2Ar), 3.90(dd, 1H, 2J=10.6, 3JH,P=4.5, 1-CHα), 4.00(dd, 1H, 1-CHβ), 4.03(t, 3H, 3J=6.6 Hz, 1'-ArOCH2), 6.88(d', 2H, J=10.1, ArH), 7.16(d', J=8.1, ArH)。
a)tert−ブチル{(R)−2−メチル−2−(3−オキソ−1,5−ジヒドロ−3λ 5 −ベンゾ[e][1,3,2]ジオキサホスフェピン−3−イルオキシ)−4−[4−(4,4,5,5,5−ペンタフルオロ−ペンチルオキシ)−フェニル]−ブチ−2−イル}−カルバメート
tert−ブチル{(R)−1−ヒドロキシ−2−メチル−4−[4−(4,4,5,5,5−ペンタフルオロ−ペンチルオキシ)−フェニル]−ブチ−2−イル}−カルバメート(40mg、0.088mmol、実施例1a)およびテトラゾール(18mg、0.26mmol、3当量、トルエンから再結晶)の乾燥THF(1ml)溶液に、3−ジエチルアミノ−1,5−ジヒドロ−ベンゾ[e][1,3,2]ジオキサホスフェピン(32μl、0.13mmol、1.5当量)を添加する。反応混合物をアルゴン下、RTで3時間撹拌する。次いで、H2O2(30%、90μl、0.88、10当量)を0℃で、激しく撹拌しながら注入する。反応混合物をさらに30分撹拌し、続いて飽和チオ硫酸ナトリウム溶液(1ml)を添加する。有機層を分離し、水性相をエーテル(3×1ml)で抽出する。合わせた有機抽出物を塩水で洗浄し、MgSO4で乾燥し、蒸発乾固する。粗物質をフラッシュクロマトグラフィー(MTBE/ヘキサン 1:1)で精製し、無色結晶を得る:MS(ESI+): 655(MNH4 +), 638(MH+), 538(MH+-Boc). 1H-NMR(400 MHz, CDCl3): δ 1.36(s, 3H, 2-Me), 1.44(s, 9H, tBu), 1.80(cm, 1H, 3-CHα), 2.02-2.20(m, 3H, 3-CHα + 2'-CH2), 2.27(cm, 2H, 3'-CH2), 2.59(t', 2H, J=8.6, 4-CH2Ar), 4.02(t, 3H, 3J=5.9, 1'-ArOCH2), 4.17(dd, 1H, 2J=9.9, 3JH,P=5.4, 1-CHα), 4.35(dd, 1H, 1-CHβ), 5.17(dd, 2H, ArCHαO, 2J=13.6, 3JH,P=15.3), 5.30(ddd, 2H, ArCHβO, 2J=13.4, 3JH,P=16.3, J=4.4), 6.82(d', 2H, J=8.9, ArH), 7.16(d', J=8.7, ArH), 7.29-7.35(m, 2H, ArH), 7.37-7.42(m, 2H, ArH)。
tert.−ブチル{(R)−1−(ジ−tert.−ブトキシ−ホスホリルオキシメチル)−3−[4−(5−フルオロペンチル−オキシ)−フェニル]−1−メチル−プロピル}−カルバメート(90mg、0.16mmol)のジオキサン(0.75ml)溶液に、4M HClのジオキサン(0.25ml)溶液を添加する。2時間撹拌後、濁った溶液を蒸発する。無色の蝋状残渣を乾燥エーテル(5ml)と超音波処理し、ベージュ色沈殿を得る。固体を濾取し、乾燥エーテルで洗浄し、真空乾燥して黄褐色粉末を得る:融点237−241℃、MS(ESI+): 727(M2H+), 364(MH+), 1H-NMR(400 MHz, CD3OD): δ 1.37(s, 3H, 2-Me), 1.60(cm, 2H, 3'-CH2), 1.69-1.93(m, 5H, 3-CHα & 2'-CH2 & 4'-CH2), 2.01(cm, 2H, 3-CHβ), 2.55-2.75(m, 2H, 4-CH2Ar), 3.86(dd, 1H, 2J=10.3, 3JH,P=4.6, 1-CHα), 3.97(dd, 1H, 1-CHβ), 3.99(t, 3H, 3J=6.8 Hz, 1'-ArOCH2), 4.46(dt, 2H, 2JH,F=46.2, 3JH,H=6.9, 5'-CH2F), 6.84(d', 2H, J=10.4, ArH), 7.16(d', J=8.5, ArH)。
a)tert.−ブチル{(R)−1−(ジ−tert.−ブトキシ−ホスホリルオキシメチル)−3−[4−(5−フルオロペンチル−オキシ)−フェニル]−1−メチル−プロピル}−カルバメート
tert−ブチル{(R)−1−ヒドロキシ−2−メチル−4−[4−(5−フルオロ−ペンチルオキシ)−フェニル]−ブチ−2−イル}−カルバメート(80mg、0.21mmol、実施例2a)およびテトラゾール(88mg、1.26mmol、6当量、トルエンから再結晶)の乾燥THF(2ml)溶液に、ジ−tert.−ブチルジエチルホスホロアミデート(174μl、0.63mmol、3当量)を添加する。反応混合物をアルゴン下、RTで2時間撹拌する。トリエチルアミン(320ml、2.3mmol、11当量)の添加後、過酸化水素(30%、213μl、2.1mmol、10当量)を0℃で激しく撹拌しながら注入する。反応混合物をさらに30分撹拌し、続いて飽和チオ硫酸ナトリウム溶液(1ml)を添加する。有機層を分離し、水性相をエーテル(3×1ml)で抽出する。合わせた有機抽出物を塩水で洗浄し、MgSO4で乾燥し、蒸発乾固する。粗物質をフラッシュクロマトグラフィー(MTBE/Hx 1:1)で精製し、無色結晶を得る:MS(ESI+): 598(MNa+), 593(MNH4 +), 576(MH+), 1H-NMR(400 MHz, CDCl3): δ 1.37(s, 3H, 2-Me), 1.46(s, 9H, Boc), 1.52(s, 18H, tBuO), 1.62(cm, 2H, 3'-CH2), 1.70-1.98(m, 5H, 3-CHα & 2'-CH2 & 4'-CH2), 2.08(cm, 1H, 3-CHβ), 2.48(cm, 2H, 4-CH2Ar), 3.88(dd, 1H, 2J=10.1, 3JH,P=5.5, 1-CHα), 3.96(t, 3H, 3J=6.5, 1'-ArOCH2), 4.07(dd, 1H, 1-CHβ), 4.44(dt, 2H, 2JH,F=44.2, 3JH,H=6.7, 5'-CH2F), 6.82(d', 2H, J=9.1, ArH), 7.10(d', J=8.9, ArH)。
2−メチル−4−{2−[4−(4,4,4−トリフルオロ−ブトキシ)−フェニル]−エチル}−4,5−ジヒドロ−オキサゾール−4−イル)−メタノール(200mg、0.57mmol)のエタノール(5ml)溶液に、濃塩酸(5ml)を添加する。反応混合物を85℃で4時間撹拌し、次いで濃縮して乾燥させる。残渣をAcOEtに再溶解し、ヘキサンで沈殿させる。固体を濾取し、乾燥エーテルで洗浄し、真空下乾燥して、2−アミノ−2−{2−[4−(4,4,4−トリフルオロ−ブトキシ)−フェニル]−エチル}−プロパン−1,3−ジオールの塩酸塩を白色粉末として得る。MS(ESI+): 322.2(MH+)。
a)2−メチル−4−{2−[4−(4,4,4−トリフルオロ−ブトキシ)−フェニル]−エチル}−4,5−ジヒドロ−オキサゾール−4−イル)−メタノール(一般法・方法D、スキーム3)
4−[2−(4−ヒドロキシメチル−2−メチル−4,5−ジヒドロ−オキサゾール−4−イル)−エチル]−フェノール(500mg、2.12mmol)の乾燥DMF(8ml)溶液に、不活性雰囲気下Cs2CO3(901mg、2.76mmol、1.3当量)および4−ブロモ−1,1,1−トリフルオロ−ブタン(487.8mg、2.55mmol、1.2当量)を添加する。反応混合物を、不活性雰囲気下、85℃で一晩撹拌する。NaHCO3の飽和溶液(20ml)およびAcOEt(40ml)を次いで添加する。有機層を分離し、水性相をAcOEt(3×40ml)で抽出する。合わせた有機層を塩水および1M HClで洗浄し、MgSO4で乾燥し、蒸発乾固する。フラッシュクロマトグラフィー(cyヘキサン/AcOEt(9/1)から(1/1)および(0/1))の精製により、2−メチル−4−{2−[4−(4,4,4−トリフルオロ−ブトキシ)−フェニル]−エチル}−4,5−ジヒドロ−オキサゾール−4−イル)−メタノールを無色油状物として得る。
4−[2−(4−ヒドロキシメチル−2−メチル−4,5−ジヒドロ−オキサゾール−4−イル)−エチル]−フェノール(300mg、1.27mmol)の乾燥THF(6ml)溶液に、不活性雰囲気下、ポリスチレン支持されたトリフェニルホスフィン(挿入3mmol.g−1、1.27g、3.81mmol、3当量)、2−(3−フルオロ−4−メトキシ−フェニル)−エタノール(647.7mg、3.81mmol、3当量)およびDBAD(877.3mg、3.81mmol、3当量)を添加する。反応混合物を不活性雰囲気下、室温で一晩撹拌した。ポリスチレン支持されたトリフェニルホスフィンを次いでフリットを通して濾過し、酢酸エチルおよびメタノールで洗浄した。次いで、反応混合物を濃縮して乾燥させ、続いて4M HClのジオキサン(3ml)溶液を添加し、反応物を室温で3時間撹拌した。反応混合物をNaHCO3の飽和溶液(10ml)および酢酸エチル(40ml)の添加によりクエンチした。有機層を分離し、水性相を酢酸エチル(3×40ml)で抽出する。合わせた有機抽出物を塩水で洗浄し、MgSO4で乾燥し、蒸発乾固する。Flashmaster(cヘキサン/酢酸エチル(1/9)、酢酸エチルおよび酢酸エチル/メタノール(98/2))を使用した精製により、[4−(2−{4−[2−(3−フルオロ−4−メトキシ−フェニル)−エトキシ]−フェニル}−エチル)−2−メチル−4,5−ジヒドロ−オキサゾール−4−イル]−メタノールを無色油状物として得る。MS(ESI+): 364.2(MH+)。
(2−メチル−4−{2−[4−(6,6,6−トリフルオロ−ヘキシルオキシ)−フェニル]−エチル}−4,5−ジヒドロ−オキサゾール−4−イル)−メタノール(300mg、0.80mmol)およびテトラゾール(337.4mg、4.82mmol、6当量、トルエンから再結晶)の乾燥THF(6ml)溶液に、3−ジエチルアミノ−1,5−ジヒドロ−ベンゾ[e][1,3,2]ジオキサホスフェピン(433.5μl、1.56mmol、1.95当量)を添加する。反応混合物を、アルゴン下、室温で3時間撹拌する。次いで、H2O2(30%、75μl、4.0mmol、5当量)を0℃で激しく撹拌しながら注入する。反応混合物をさらに30分撹拌し、次いで飽和チオ硫酸ナトリウム溶液(1ml)を添加する。有機層を分離し、水性相をエーテル(3×20ml)で抽出する。合わせた有機抽出物を塩水で洗浄し、MgSO4で乾燥し、蒸発乾固する。フラッシュクロマトグラフィー(AcOEt)での精製により、リン酸ジ−tert−ブチルエステル2−メチル−4−{2−[4−(6,6,6−トリフルオロ−ヘキシルオキシ)−フェニル]−エチル}−4,5−ジヒドロ−オキサゾール−4−イルメチルエステルを無色油状物として得る。リン酸ジ−tert−ブチルエステル2−メチル−4−{2−[4−(6,6,6−トリフルオロ−ヘキシルオキシ)−フェニル]−エチル}−4,5−ジヒドロ−オキサゾール−4−イルメチルエステル(33mg、0.050mmol)のエタノール(2ml)溶液に、濃HCl(2ml)を添加する。反応混合物を85℃で2時間撹拌し、次いで濃縮して乾燥する。残渣をAcOEtに再溶解し、ヘキサンで沈殿させる。固体を濾取し、乾燥エーテルで洗浄し、真空下乾燥させてリン酸モノ−{2−アミノ−2−ヒドロキシメチル−4−[4−(6,6,6−トリフルオロ−ヘキシルオキシ)−フェニル]−ブチル}エステルを無色粉末として得る。MS(ESI-): 428.2(MH-)。
式Iの化合物は、以下のアッセイで測定するように、個々のヒトS1Pレセプターに結合親和性を有する:
スフィンゴシン−1−リン酸エステル(S1P)レセプター分布
化合物をヒトS1Pレセプター(S1P1)、(S1P3)、(S1P2)、(S1P4)および(S1P5)で試験する。機能的レセプター活性化を、安定に適当なヒトS1Pレセプターを発現するトランスフェクトしたCHOまたはRH7777から調節した膜タンパク質へのGTP[γ−35S]結合を誘発する化合物の定量により評価する。アッセイ技術は、SPA(シンチレーション近接ベースアッセイ)を使用する。簡単に、DMSOに溶解した化合物を連続的に希釈し、SPA−ビーズ(Amersham-Pharmacia)固定化S1Pレセプター発現膜タンパク質(10−20μg/ウェル)に、50mM Hepes、100mM NaCl、10mM MgCl2、10μM GDP、0.1%無脂肪BSAおよび0.2nM GTP[γ−35S](1200Ci/mmol)の存在下添加する。96ウェルマイクロタイタープレートで、RTで120分インキュベーション後、非結合GTP[γ−35S]を遠心段階により分離する。膜結合GTP[γ−35S]により発色されたSPAビーズの蛍光を、TOPcountプレートリーダー(Packard)で定量する。EC50を、標準曲線当てはめソフトウェアを使用して計算する。例えば、以下の結果が得られる:
式Iの化合物または賦形剤を、ラットに経口で胃管栄養により投与する。組織学的モニタリングのための尾の血液を、個々の基底値のために−1日目、投与後2、6、24、48および72時間後に得る。このアッセイにおいて、式Iの化合物は、0.03から3mg/kgの投与量で投与した場合、末梢血リンパ球を枯渇する。例えば、以下の結果が得られる:50%以上の末梢血リンパ球の枯渇
実施例1:0.2mg/kg経口で6時間後、0.1mg/kg経口で24時間後
実施例6:0.06mg/kg経口で6時間後、0.05mg/kg経口で24時間後
実施例14:0.03mg/kg経口で6時間後、0.04mg/kg経口で24時間後
実施例27:0.1mg/kg経口で6時間後、0.03mg/kg経口で24時間後
実施例31:0.05mg/kg経口で6時間後、0.1mg/kg経口で48時間後
実施例72:0.07mg/kg経口で6時間後、0.03mg/kg経口で48時間後
1.1 処置を必要とする対象におけるリンパ球により介在される疾患または障害、例えば上記のようなものを予防または処置する方法であり、該対象に式Iの化合物またはその薬学的に許容される塩の有効量を含む方法;
1.2 処置を必要とする対象における急性もしくは慢性移植拒絶反応またはT細胞介在炎症性もしくは自己免疫性疾患、例えば上記のようなものを予防または処置する方法であり、該対象に式Iの化合物またはその薬学的に許容される塩の有効量を含む方法;
Claims (3)
- 遊離形または塩形の、式I
R1はメチルであり;
R2はベンゼン環の4位に存在する、式(c)
−Y ' − ( CH 2 ) n − ( CF 2 ) m −CH p F q ( c )
の基であり、ここで、
Y’は直接結合、O、CO、CHOHまたはC=NOR 6 であり、ここで、R 6 はH、C 1−4 アルキル、C 2−4 アルケニル、C 2−4 アルキニルまたはベンジルであり;
nは0、1、2、3、4または5であり;
mは0、1、2、3、4、5または6であり(但し、n+m=3〜8);
pおよびqの各々は0、1、2または3であり(但し、p+q=3);
鎖:− ( CH 2 ) n − ( CF 2 ) m −CH p F q には、1個の炭素−炭素二重結合または三重結合、1個のCOあるいは1個または2個の酸素原子が介在しているかまたは介在しておらず
R 2 は少なくとも2個のフッ素原子を有し;
R3は基:−Z−X2であり、ここで、ZはCH2、CHF、CF2またはCHMeであり、X2はOHまたは式(a)
の基であり;そして、
R4およびR5の各々は独立してH、1個、2個もしくは3個のハロゲン原子で置換されているかまたは置換されていないC1−4アルキル、またはアシルである。]
で表される化合物。 - R 2 が以下の群から選択された基である、請求項1記載の遊離形または塩形の化合物:
−Y−CnF2n+1(ここで、n=3〜8であり、そしてYはCH2、OまたはC=Oである);
−Y−CH2CnF2n+1(ここで、n=1〜7であり、そしてYはCH2、OまたはC=Oである);
−Y−CH2CH2CnF2n+1(ここで、n=1〜6であり、そしてYはCH2、OまたはC=Oである);
−Y−CH2CH2CH2CnF2n+1(ここで、n=1〜5であり、そしてYはCH2、OまたはC=Oである);
−Y−(CH2)nCF3(ここで、n=1〜6であり、そしてYはCH2、OまたはC=Oである);
−Y−(CH2)nCF2CH3(ここで、n=1〜4であり、そしてYはCH2、OまたはC=Oである);
−Y−(CH2)n(CF2)mCHF2(ここで、n=0〜3、m=1〜6、n+m=3〜7であり、そしてYはCH2、OまたはC=Oである);および
−Y−(CH2)nC(O)CF3(ここで、n=1〜5であり、そしてYはCH2、OまたはC=Oである) - リンパ球により介在される疾病または疾患の予防または処置、および急性もしくは慢性移植拒絶反応またはT細胞介在炎症性もしくは自己免疫性疾患の予防または処置のための、請求項1または2に記載の遊離形または塩形の化合物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0221313A GB0221313D0 (en) | 2002-09-13 | 2002-09-13 | Organic compounds |
GB0222617A GB0222617D0 (en) | 2002-09-30 | 2002-09-30 | Organic compounds |
PCT/EP2003/010175 WO2004024673A1 (en) | 2002-09-13 | 2003-09-12 | Amino-propanol derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008154010A Division JP2009001567A (ja) | 2002-09-13 | 2008-06-12 | アミノ−プロパノール誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005538169A JP2005538169A (ja) | 2005-12-15 |
JP4166218B2 true JP4166218B2 (ja) | 2008-10-15 |
Family
ID=31995702
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004535500A Expired - Fee Related JP4166218B2 (ja) | 2002-09-13 | 2003-09-12 | アミノ−プロパノール誘導体 |
JP2008154010A Pending JP2009001567A (ja) | 2002-09-13 | 2008-06-12 | アミノ−プロパノール誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008154010A Pending JP2009001567A (ja) | 2002-09-13 | 2008-06-12 | アミノ−プロパノール誘導体 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7612238B2 (ja) |
EP (1) | EP1539674A1 (ja) |
JP (2) | JP4166218B2 (ja) |
CN (1) | CN100516024C (ja) |
AU (1) | AU2003273865A1 (ja) |
BR (1) | BR0314113A (ja) |
CA (1) | CA2497067A1 (ja) |
WO (1) | WO2004024673A1 (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITRM20010688A1 (it) | 2001-11-21 | 2003-05-21 | Univ Roma | Composti immunoregolatori. |
BR0306811A (pt) | 2002-01-11 | 2004-10-26 | Sankyo Co | Composto, éster farmacologicamente aceitável do mesmo, composição farmacêutica e métodos para prevenção ou tratamento de doenças autoimunes, da artrite reumatóide e da rejeição causada pelo transplante de vários órgãos em um mamìfero |
EP1546110A4 (en) | 2002-07-30 | 2008-03-26 | Univ Virginia | ACTIVE COMPOUNDS IN THE SIGNALING OF SPHINGOSINE 1-PHOSPHATE |
EP2617711A1 (en) * | 2002-09-19 | 2013-07-24 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivatives, salts thereof and immunosuppressive agents |
EP1594508B1 (en) * | 2003-02-11 | 2012-08-08 | Irm Llc | Novel bicyclic compounds and compositions |
KR101005171B1 (ko) | 2003-02-18 | 2011-01-04 | 교린 세이야꾸 가부시키 가이샤 | 아미노포스폰산 유도체와 그 부가염 및 s1p 수용체조절제 |
BRPI0410025A (pt) | 2003-04-30 | 2006-04-25 | Novartis Ag | derivados de amino-propanol como modulador do receptor de esfingosina-1-fosfato |
CN102175786B (zh) * | 2003-08-28 | 2013-07-17 | 诺瓦提斯公司 | 氨基丙醇衍生物 |
WO2005041899A2 (en) | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
GB0329498D0 (en) | 2003-12-19 | 2004-01-28 | Novartis Ag | Organic compounds |
AU2005215320B2 (en) | 2004-02-24 | 2008-04-17 | Sankyo Company, Limited | Amino alcohol compound |
GB0411929D0 (en) * | 2004-05-27 | 2004-06-30 | Novartis Ag | Organic compounds |
EP1772145B1 (en) | 2004-07-16 | 2011-03-23 | Kyorin Pharmaceutical Co., Ltd. | Method of effectively using medicine and method concerning prevention of side effect |
TW200611687A (en) * | 2004-07-29 | 2006-04-16 | Sankyo Co | Pharmaceutical compositions used for immunosuppressant |
CN1993333B (zh) | 2004-08-04 | 2012-08-01 | 大正制药株式会社 | ***衍生物 |
US20060223866A1 (en) * | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
US7241812B2 (en) * | 2004-08-13 | 2007-07-10 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
JP4792400B2 (ja) * | 2004-10-12 | 2011-10-12 | 杏林製薬株式会社 | 2−アミノ−2−[2−[4−(3−ベンジルオキシフェニルチオ)−2−クロロフェニル]エチル]−1,3−プロパンジオール塩酸塩又はその水和物の製造方法及びその製造中間体 |
JP2008530135A (ja) | 2005-02-14 | 2008-08-07 | ユニバーシティ オブ バージニア パテント ファンデーション | アミノ基およびフェニル基で置換されたシクロアルカンならびに5員の複素環を含むスフィンゴシン=1−リン酸アゴニスト |
TWI418350B (zh) * | 2005-06-24 | 2013-12-11 | Sankyo Co | 含有ppar調節劑之醫藥組成物的用途 |
GB0513431D0 (en) * | 2005-06-30 | 2005-08-10 | Kherion Technology Ltd | Prophylactic compositions and uses |
WO2007043433A1 (ja) * | 2005-10-07 | 2007-04-19 | Kyorin Pharmaceutical Co., Ltd. | 2-アミノ-1,3-プロパンジオール誘導体を有効成分とする肝臓疾患治療剤および肝臓疾患治療方法 |
CN101346346B (zh) * | 2005-12-15 | 2012-08-22 | 田边三菱制药株式会社 | 胺化合物及其医药用途 |
AU2007209961A1 (en) | 2006-01-27 | 2007-08-09 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
EP1988083B1 (en) * | 2006-02-03 | 2014-04-02 | Taisho Pharmaceutical Co., Ltd. | Triazole derivative |
EP1988081B1 (en) | 2006-02-06 | 2012-10-17 | Taisho Pharmaceutical Co., Ltd | Binding inhibitor of sphingosine-1-phosphate |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
JP2009526073A (ja) | 2006-02-09 | 2009-07-16 | ユニバーシティ オブ バージニア パテント ファンデーション | 二環式スフィンゴシン−1−リン酸受容体アナログ |
DK2058317T3 (da) * | 2006-08-08 | 2014-01-06 | Kyorin Seiyaku Kk | Aminophosphorsyreesterderivat og S1P receptormodulator indeholdende samme som aktiv ingrediens |
TWI396677B (zh) | 2006-08-08 | 2013-05-21 | Kyorin Seiyaku Kk | An amine alcohol derivative and an immunosuppressive agent for use as an active ingredient |
EP2081888A1 (en) * | 2006-09-08 | 2009-07-29 | Novartis AG | N-biaryl (hetero) arylsulphonamide derivatives useful in the treatment of diseases mediated by lymphocytes interactions |
EP2075230B1 (en) | 2006-10-18 | 2014-04-30 | Mitsubishi Gas Chemical Company, Inc. | Process for producing monopersulfuric acid and monopersulfuric acid |
EP2099741A2 (en) | 2006-11-21 | 2009-09-16 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
AU2007323557A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
EP2097397A1 (en) | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
JP5311057B2 (ja) | 2007-08-01 | 2013-10-09 | 大正製薬株式会社 | S1p1結合阻害物質 |
RU2536040C2 (ru) | 2007-11-01 | 2014-12-20 | Акусела Инк. | Производные амина и их применение для лечения офтальмологических заболеваний и расстройств |
US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
CN101768086B (zh) * | 2008-12-29 | 2014-03-26 | 北京富龙康泰生物技术有限公司 | 氨基甲醇衍生物及其盐类化合物及其合成方法和其药物用途 |
CN102260177A (zh) * | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 丙二醇类衍生物、其制备方法和其药物组合物与用途 |
CN102260178A (zh) * | 2010-05-25 | 2011-11-30 | 中国医学科学院药物研究所 | 羟基丙二醇类衍生物、其制备方法和其药物组合物与用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2126658T3 (es) * | 1992-10-21 | 1999-04-01 | Yoshitomi Pharmaceutical | Compuesto de 2-amino-1,3-propanodiol e inmunosupresor. |
PT778263E (pt) * | 1994-08-22 | 2002-06-28 | Mitsubishi Pharma Corp | Composto de benzeno e sua utilizacao farmaceutica |
EP1319651B1 (en) | 1997-04-04 | 2005-06-29 | Mitsubishi Pharma Corporation | 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor |
JP2004507552A (ja) | 2000-08-31 | 2004-03-11 | メルク エンド カムパニー インコーポレーテッド | 免疫調節剤としてのリン酸誘導体 |
ATE314383T1 (de) * | 2001-03-26 | 2006-01-15 | Novartis Pharma Gmbh | 2-amino-propanol derivate |
-
2003
- 2003-09-12 EP EP03757830A patent/EP1539674A1/en not_active Withdrawn
- 2003-09-12 BR BR0314113-6A patent/BR0314113A/pt not_active IP Right Cessation
- 2003-09-12 CA CA002497067A patent/CA2497067A1/en not_active Abandoned
- 2003-09-12 AU AU2003273865A patent/AU2003273865A1/en not_active Abandoned
- 2003-09-12 WO PCT/EP2003/010175 patent/WO2004024673A1/en active Application Filing
- 2003-09-12 JP JP2004535500A patent/JP4166218B2/ja not_active Expired - Fee Related
- 2003-09-12 US US10/526,760 patent/US7612238B2/en not_active Expired - Fee Related
- 2003-09-12 CN CNB038215780A patent/CN100516024C/zh not_active Expired - Fee Related
-
2008
- 2008-06-12 JP JP2008154010A patent/JP2009001567A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN100516024C (zh) | 2009-07-22 |
JP2009001567A (ja) | 2009-01-08 |
EP1539674A1 (en) | 2005-06-15 |
CN1681770A (zh) | 2005-10-12 |
WO2004024673A1 (en) | 2004-03-25 |
CA2497067A1 (en) | 2004-03-25 |
US7612238B2 (en) | 2009-11-03 |
AU2003273865A1 (en) | 2004-04-30 |
US20060166940A1 (en) | 2006-07-27 |
BR0314113A (pt) | 2005-07-12 |
JP2005538169A (ja) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4166218B2 (ja) | アミノ−プロパノール誘導体 | |
JP4638410B2 (ja) | スフィンゴシン−1−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体 | |
JP4603531B2 (ja) | スフィンゴシン−1−ホスフェートレセプターモジュレーターとしての、アミノプロパノール誘導体 | |
EP1377593B1 (en) | 2-amino-propanol derivatives | |
US7728020B2 (en) | Amino acid derivatives | |
US7928093B2 (en) | Amino-propanol derivatives | |
EP1660449B1 (en) | Aminopropanol derivatives | |
KR100879831B1 (ko) | 아미노산 유도체 | |
AU2002257719A1 (en) | 2-amino-propanol derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20071218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080306 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080313 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080512 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080612 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080715 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080729 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110808 Year of fee payment: 3 |
|
LAPS | Cancellation because of no payment of annual fees |